Search Browse Earnings

Grace Therapeutics, Inc.

Nasdaq:GRCE

Pharmaceutical Preparations·PRINCETON, NJ

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Grace Therapeutics, Inc. — SlamSEC

Revenue

$100.0M

FY 2023

Adj. EBITDA

-$12.8M

-12.8% margin

FY 2025

Net Income

-$12.9M

-12.9% margin

FY 2025

EPS (Diluted)

-$1.35

FY 2025

Stock Price

$3.90

+4.6%

2026-03-09

52W Range

$1.75 – $4.30

P/E Ratio

-2.9x

Market Cap

$60.3M

Cash

$23.0M

FY 2025

Total Debt

—

Net Cash

$23.0M

FY 2023

Enterprise Value

$37.3M

Debt / EBITDA

1.8x

FY 2023

EV / EBITDA

-2.9x

Employees

—